HK1173181A1 - Medicament and agent for treating and diagnosing immune disorders and their use - Google Patents

Medicament and agent for treating and diagnosing immune disorders and their use

Info

Publication number
HK1173181A1
HK1173181A1 HK13100374.1A HK13100374A HK1173181A1 HK 1173181 A1 HK1173181 A1 HK 1173181A1 HK 13100374 A HK13100374 A HK 13100374A HK 1173181 A1 HK1173181 A1 HK 1173181A1
Authority
HK
Hong Kong
Prior art keywords
medicament
treating
agent
immune disorders
diagnosing immune
Prior art date
Application number
HK13100374.1A
Other languages
English (en)
Chinese (zh)
Inventor
朱正侖
高紅
Original Assignee
朱正侖
高紅
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 朱正侖, 高紅 filed Critical 朱正侖
Publication of HK1173181A1 publication Critical patent/HK1173181A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK13100374.1A 2009-07-15 2013-01-10 Medicament and agent for treating and diagnosing immune disorders and their use HK1173181A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22585209P 2009-07-15 2009-07-15
PCT/US2010/042126 WO2011008947A2 (fr) 2009-07-15 2010-07-15 Traitement et diagnostic de troubles immunitaires

Publications (1)

Publication Number Publication Date
HK1173181A1 true HK1173181A1 (en) 2013-05-10

Family

ID=43450204

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13100374.1A HK1173181A1 (en) 2009-07-15 2013-01-10 Medicament and agent for treating and diagnosing immune disorders and their use

Country Status (8)

Country Link
US (4) US8741865B2 (fr)
EP (2) EP3524274A3 (fr)
CN (1) CN102575250B (fr)
DK (1) DK2454372T3 (fr)
ES (1) ES2707590T3 (fr)
HK (1) HK1173181A1 (fr)
HU (1) HUE042736T2 (fr)
WO (1) WO2011008947A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011008947A2 (fr) 2009-07-15 2011-01-20 Zhenglun Zhu Traitement et diagnostic de troubles immunitaires
CN103415615B (zh) * 2010-11-24 2015-11-25 高红 扩增造血干细胞
US10066272B2 (en) * 2011-06-10 2018-09-04 Zhenglun Zhu Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof
US9428748B2 (en) * 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
SG11201803599PA (en) * 2015-11-11 2018-05-30 Zhenglun Zhu Method of modifying macrophage differentiation and immunity
IL260987B1 (en) 2016-02-04 2024-05-01 Zhenglun Zhu Treatment and diagnosis of inflammatory disorders
JP7289289B2 (ja) * 2017-03-28 2023-06-09 ツェンラン・チュー 腫瘍性疾患を治療する方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
US5583153A (en) * 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
EP1222933A1 (fr) 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Génération et/ou réduction de nouveau tissu pulmonaire dans un poumon atteint, par modulation de la voie Wnt
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060247193A1 (en) * 2003-02-10 2006-11-02 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference
WO2006086345A2 (fr) * 2005-02-07 2006-08-17 The Trustees Of Columbia University In The City Of New York Methodes de traitement ou de prevention du cancer de la prostate hormono-resistant au moyen de petits arn interferents specifiques de la protocadherine-pc, ou d'autres inhibiteurs de l'expression ou de l'activite de la protocadherine-pc
EP1948680A4 (fr) * 2005-10-28 2010-01-13 Univ California Methodes et composes de detection et d'isolement de cellules lymphomatiques
US20070161031A1 (en) * 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
EP2021499A4 (fr) * 2005-12-16 2010-02-17 Univ Leland Stanford Junior Reseaux fonctionnels pour la caracterisation a grande cadence d'elements regulant l'expression genique
WO2007101063A2 (fr) * 2006-02-22 2007-09-07 Zhu M D Zhenglun Traitement de troubles liés au développement
WO2011008947A2 (fr) * 2009-07-15 2011-01-20 Zhenglun Zhu Traitement et diagnostic de troubles immunitaires

Also Published As

Publication number Publication date
ES2707590T3 (es) 2019-04-04
EP2454372B1 (fr) 2018-10-03
EP2454372A4 (fr) 2013-10-16
US8741865B2 (en) 2014-06-03
EP3524274A3 (fr) 2020-01-01
CN102575250B (zh) 2014-05-28
US11248252B2 (en) 2022-02-15
CN102575250A (zh) 2012-07-11
WO2011008947A2 (fr) 2011-01-20
HUE042736T2 (hu) 2019-07-29
WO2011008947A3 (fr) 2011-07-21
US20240132935A1 (en) 2024-04-25
DK2454372T3 (en) 2019-01-28
US20120183553A1 (en) 2012-07-19
US20140315205A1 (en) 2014-10-23
US20180282785A1 (en) 2018-10-04
EP2454372A2 (fr) 2012-05-23
EP3524274A2 (fr) 2019-08-14

Similar Documents

Publication Publication Date Title
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
EP2621588A4 (fr) Procédés et compositions pour le traitement de maladie en utilisant l'inhalation
HK1173181A1 (en) Medicament and agent for treating and diagnosing immune disorders and their use
GB0922085D0 (en) Cancer diagnosis and treatment
EP2586448A4 (fr) Agent d'amélioration des propriétés cutanées, destiné à être administré par voie orale
EP2412328A4 (fr) Dispositif de traitement médical
EP2405928A4 (fr) Procédés de traitement et de diagnostic pour troubles d'hypersensibilité
PL2410922T3 (pl) Urządzenie do przeprowadzania procedur diagnostycznych i/lub terapeutycznych
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
GB0918392D0 (en) Diagnostic and therapeutic methods
IL240560A0 (en) Preparations and methods for tumor diagnosis and treatment
GB0920258D0 (en) New medical agents and use thereof
EP2387407A4 (fr) Médicament destiné au traitement de la douleur et de l'inflammation
IL229704A (en) Means and methods for diagnosing multiple sclerosis and causing its treatment
HK1203190A1 (en) Compounds for use in imaging, diagnosing and or treatment of diseases of the central nervous system
EP2361317A4 (fr) Utilisation de eif3m pour le diagnostic et le traitement du cancer
PT2630475T (pt) Método de diagnóstico e tratamento
EP2488198A4 (fr) Traitement et diagnostic des troubles inflammatoires
EP2438167A4 (fr) Molécules thérapeutiques et diagnostiques
GB0901837D0 (en) Cancer diagnosis and treatment
GB0900484D0 (en) Therapeutic agent
IL222482A0 (en) Methods and compositions for the treatment of fluid accumulation in and/or under the retina
EP2643470A4 (fr) Compositions et procédés pour diagnostiquer et traiter des maladies et troubles associés à d-dt
ZA201203286B (en) Therapeutic and diagnostic applications against trypanosomosis
HRP20151393T8 (hr) UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE